Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Chinese Pharmas Seen As Major Beneficiaries Of Health Reform

This article was originally published in PharmAsia News

Executive Summary

North China Pharmaceutical and Yunnan Balyao Group are seen as early winners of the government's newly disclosed three-year guideline for reforming the nation's health care system. North China makes antibiotics and vitamins and is seen benefiting from an increased demand for its products. Yunnan makes traditional Chinese medicines. Also seen benefiting is Harbin Pharmaceutical, a penicillin producer. Part of the health care reform design focuses on expanding medical insurance coverage to all rural and urban residents. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071542

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel